US Oncology, Inc., the leading oncology services company uniting the nation's largest cancer treatment and research network to expand patient access to high-quality, cost-effective cancer care and advance the science of cancer care, has been named to FORTUNE magazine's World's Most Admired Companies list for 2010. The company ranks second in the Health Care: Pharmacy and Other category, up from third place in 2009. This is the fifth time US Oncology has been honored with FORTUNE magazine's World's Most Admired Companies distinction, having been named to the list in 2003, 2004, 2007, and 2009.
The magazine's annual list is considered the definitive report card on corporate reputations. Ranked by top industry executives and financial analysts on nine areas of leadership, US Oncology placed first in the categories of People Management and Social Responsibility, and second in its sector in the categories of Innovation, Use of Corporate Assets, and Quality of Management. The company ranks in the top five of eight categories, including Long-Term Investment (ranked 3), Quality of Product Services and Global Competitiveness (ranked 5).
US Oncology uses its expertise, insight and passion for eradicating cancer to develop innovative solutions that advance the quality and cost-effectiveness of cancer care. Through the use of technology, research, world-class evidence-based pathways, and patient education and support, the company works with physicians, patients, payers and the medical industry to improve patients' lives and advance the science and value of cancer care; and enables physicians to deliver this high quality care in the communities where patients live.
Revolutionizing brain tumor treatment: the rise of AI in neuro-oncology